Acute pancreatitis associated with the administration of meglumine antimonate for the treatment of visceral leishmaniasis.
F
F
de Lalla
G
G
Pellizzer
L
L
Gradoni
M
M
Vespignani
M
M
Franzetti
C
C
Stecca
D000208:Acute Disease; D000328:Adult; D000965:Antimony / Q000009:adverse effects* / Q000627:therapeutic use; D000981:Antiprotozoal Agents / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D005869:Ghana; D006801:Humans; D007898:Leishmaniasis, Visceral / Q000188:drug therapy*; D008536:Meglumine / Q000009:adverse effects* / Q000627:therapeutic use; D000077485:Meglumine Antimoniate; D009942:Organometallic Compounds / Q000009:adverse effects* / Q000627:therapeutic use; D010195:Pancreatitis / Q000139:chemically induced*
D000981:Antiprotozoal Agents; D009942:Organometallic Compounds; D008536:Meglumine; D000077485:Meglumine Antimoniate; D000965:Antimony